Eric Chang, MD, FASTRO

Eric L. Chang, MD, FASTRO uses advanced radiation therapy techniques to treat a variety of benign and malignant brain tumors, and spine tumors. He is considered a world authority in the use of radiation therapy in the treatment of benign conditions and malignant tumors of the central nervous system, and is highly experienced in handling both routine cases and the most complex cases requiring radiotherapeutic evaluation in a multi-disciplinary setting of experts comprising neuro-radiation oncologists, neurosurgeons and neuro-oncologists, and neuro-radiologists.

Prior to joining the Keck School of Medicine of USC as Professor and Chair of Radiation Oncology, Dr. Chang was on the faculty as an attending radiation oncologist at The University of Texas M. D. Anderson Cancer Center for over 12 years, rising to an academic rank of Professor. Having established the first Gamma Knife radiosurgery program at M. D. Anderson which treats over 450 patients a year, he served as the Director of the CNS Stereotactic Radiation Program comprising the Gamma Knife program, and the Stereotactic Body Radiation Therapy (SBRT) program for spine which treats over 100 spine patients a year. He is board certified by the American Board of Radiology in radiation oncology and specializes in the radiotherapeutic evaluation and management of patients with tumors of the central nervous system. He attended Harvard Medical School where he received his Doctorate in Medicine.

Dr. Chang's post-graduate training was conducted at the Harvard Joint Center for Radiation Therapy, in Boston, Massachusetts. He has held research leadership roles including having served as member, and Chair of the M. D. Anderson Cancer Center Clinical Research Committee (CRC) Chair. He is the 2011 CNS track leader for the American Society for Clinical Oncology (ASCO) Scientific Program Committee, and member of the ASCO Cancer Education Committee. Dr. Chang is currently the co-leader for the American Society of Radiation Oncology (ASTRO) brain metastasis guidelines development task force and member of the Annual Program Committee of the Educational Council of ASTRO. He is a current member of the American College of Radiology Appropriateness Criteria Expert Panel on bone metastases. He has been listed in the Best Doctors Directory. Dr. Chang led a phase III randomized controlled trial on brain metastasis published in the Lancet Oncology 2009 which is starting to change the practice patterns for metastatic brain disease. Dr. Chang has been selected as a plenary speaker for past meetings of ASTRO and the American Association for Neurological Surgeons (AANS). He has authored or co-authored over 100 peer-reviewed papers and abstracts.